» Articles » PMID: 33794833

Extracellular Vesicles-derived MicroRNA-222 Promotes Immune Escape Via Interacting with ATF3 to Regulate AKT1 Transcription in Colorectal Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 Apr 2
PMID 33794833
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immunotherapy has been recently established as a new direction for the treatment of colorectal cancer (CRC), a gastrointestinal cancer. In this investigation, we aimed to expound how the posttranscriptional regulation modulated by microRNA-222 (miR-222) from mesenchymal stem cells-derived extracellular vesicles (MSC-EVs) affected the AKT pathway and the immune escape in CRC.

Methods: CRC cell malignant phenotype, including proliferation, migration, invasion, and apoptosis, was firstly detected after co-culture with MSC-EVs. miRNAs with differential changes in CRC cells before and after EVs treatment were filtered by microarray analysis. miR-222 was then downregulated to examine its role in CRC cells in response to EVs. Cells were implanted in mice to induce xenograft tumors, and infiltrating T cells was assessed by immunohistochemistry. The mRNA microarray was used to screen target genes, followed by rescue experiments. ChIP and western blot were conducted to validate the downstream biomolecule of ATF3.

Results: After treatment of CRC cells with MSC-EVs, the expression of miR-222 was upregulated, and cell activity was increased. Inhibition of miR-222 decreased CRC malignant aggressiveness in vitro and reduced tumorigenesis and immune escape in vivo. miR-222 targeted and bound to ATF3. Downregulation of ATF3 enhanced CRC cell malignant aggressiveness, tumorigenic capacity and immune escape. Mechanistically, ATF3 inhibited AKT1 transcription and mediated the AKT pathway.

Conclusion: MSC-EVs carry miR-222 to promote CRC cell malignant aggressiveness and immune escape. miR-222 targets and binds to ATF3, which inhibits AKT1 transcriptional activity and thereby mediates the AKT pathway.

Citing Articles

LncRNA SNHG16 Drives PD-L1-Mediated Immune Escape in Colorectal Cancer through Regulating miR-324-3p/ELK4 Signaling.

Chen Z, Wu Z, Wu M, Zhang Y, Hou S, Wang X Biochem Genet. 2024; .

PMID: 39688781 DOI: 10.1007/s10528-024-11000-3.


Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms.

Han H, He T, Wu Y, He T, Zhou W Front Cell Dev Biol. 2024; 12:1441081.

PMID: 39184916 PMC: 11341543. DOI: 10.3389/fcell.2024.1441081.


Unveiling the multifaceted roles of microRNAs in extracellular vesicles derived from mesenchymal stem cells: implications in tumor progression and therapeutic interventions.

Hu S, Zhang C, Ma Q, Li M, Yu X, Zhang H Front Pharmacol. 2024; 15:1438177.

PMID: 39161894 PMC: 11330784. DOI: 10.3389/fphar.2024.1438177.


Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells.

Garza Trevino E, Quiroz Reyes A, Delgado Gonzalez P, Rojas Murillo J, Islas J, Alonso S Int J Mol Sci. 2024; 25(14).

PMID: 39063032 PMC: 11276748. DOI: 10.3390/ijms25147791.


Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression.

Zhang Y, Wang C, Li J Exp Hematol Oncol. 2024; 13(1):64.

PMID: 38951845 PMC: 11218091. DOI: 10.1186/s40164-024-00532-4.


References
1.
Jiang K, Li G, Chen W, Song L, Wei T, Li Z . Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas. Onco Targets Ther. 2020; 13:1311-1319. PMC: 7025673. DOI: 10.2147/OTT.S231361. View

2.
Huang R, Zhang D, Li F, Xiao Z, Wu M, Shi D . Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells. Oncol Lett. 2017; 13(5):3379-3386. PMC: 5431327. DOI: 10.3892/ol.2017.5891. View

3.
Desmond B, Dennett E, Danielson K . Circulating Extracellular Vesicle MicroRNA as Diagnostic Biomarkers in Early Colorectal Cancer-A Review. Cancers (Basel). 2019; 12(1). PMC: 7016718. DOI: 10.3390/cancers12010052. View

4.
Kato T, Fahrmann J, Hanash S, Vykoukal J . Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. Cells. 2020; 9(6). PMC: 7349483. DOI: 10.3390/cells9061518. View

5.
Borgovan T, Crawford L, Nwizu C, Quesenberry P . Stem cells and extracellular vesicles: biological regulators of physiology and disease. Am J Physiol Cell Physiol. 2019; 317(2):C155-C166. DOI: 10.1152/ajpcell.00017.2019. View